P. Sayyed

Sustained Polymeric Delivery of Gene Silencing Antisense ODNs, siRNA, DNAzymes and Ribozymes: In Vitro and In Vivo Studies

Stephen P. Fox, M. Benboubetra, S. Akhtar, 2004, Journal of drug targeting.

Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study.

A. Salar, R. Bouabdallah, G. Follows, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.

G. Gaidano, A. Delmer, M. Trněný, 2016, The Lancet. Haematology.

Pharmacokinetics, safety, and effi cacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial

G. Gaidano, A. Delmer, M. Trněný, 2016 .

Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia.

G. Gaidano, A. Delmer, P. Sayyed, 2015, British journal of clinical pharmacology.

The cellular delivery of antisense oligonucleotides and ribozymes.

M. Hughes, S. Akhtar, P. Sayyed, 2001, Drug discovery today.

The delivery of antisense therapeutics.

J. Double, M. Bibby, M. Hughes, 2000, Advanced drug delivery reviews.

Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab

G. Gaidano, A. Delmer, P. Sayyed, 2012 .

A Two-Stage Phase Ib Study to Investigate the Pharmacokinetics, Safety and Tolerability of Subcutaneous Rituximab In Patients with Follicular Lymphoma as Part of Maintenance Treatment

A. Salar, R. Bouabdallah, P. Sayyed, 2010 .

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types.

B. Solomon, D. Yardley, A. Drakaki, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

MORPHEUS: A phase Ib/II trial platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT) combinations in patients (pts) with gastric or pancreatic cancer.

J. Lacy, T. Bekaii-Saab, O. Rahma, 2018 .